Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented t
Novocure Announces Upcoming Investor Events
07:00am, Tuesday, 27'th May 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host
NovoCure: Loading Up On Growth Catalysts
03:12am, Saturday, 24'th May 2025
NovoCure's Q1 earnings beat and strong commercial momentum, especially with Optune Lua in NSCLC, signal renewed growth potential and investor optimism. Key catalysts ahead include the PANOVA-3 data at
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
11:00am, Thursday, 15'th May 2025
The mean of analysts' price targets for NovoCure (NVCR) points to a 105.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
10:55am, Tuesday, 29'th Apr 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the posit
Why NovoCure Stock Skyrocketed This Week
01:21pm, Friday, 25'th Apr 2025
Shares of NovoCure (NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m.
Why NovoCure Stock Leaped 4% Higher Today
07:03pm, Thursday, 24'th Apr 2025
Thursday morning NovoCure (NVCR 4.28%) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess o
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
12:39pm, Thursday, 24'th Apr 2025
NovoCure Ltd NVCR reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents.
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 24'th Apr 2025
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript
10:34am, Thursday, 24'th Apr 2025
NovoCure Limited (NASDAQ:NVCR ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Executive Chairman Ashley Cordova - CEO Christoph Brac
NovoCure Surpasses Q1 Expectations
09:25am, Thursday, 24'th Apr 2025
NovoCure (NVCR 7.15%), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with rev
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Thursday, 24'th Apr 2025
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.36 per share a year ago.
Novocure Reports First Quarter 2025 Financial Results
07:00am, Thursday, 24'th Apr 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend surviva
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for
